ATE325341T1 - Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden - Google Patents

Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden

Info

Publication number
ATE325341T1
ATE325341T1 AT02760451T AT02760451T ATE325341T1 AT E325341 T1 ATE325341 T1 AT E325341T1 AT 02760451 T AT02760451 T AT 02760451T AT 02760451 T AT02760451 T AT 02760451T AT E325341 T1 ATE325341 T1 AT E325341T1
Authority
AT
Austria
Prior art keywords
bases
phosphodiesteroligonucleotides
apoptosis
conformation
inducing
Prior art date
Application number
AT02760451T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Zdenek Richard Holan
Stephanie Reader
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE325341T1 publication Critical patent/ATE325341T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
AT02760451T 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden ATE325341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17

Publications (1)

Publication Number Publication Date
ATE325341T1 true ATE325341T1 (de) 2006-06-15

Family

ID=23215136

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02760451T ATE325341T1 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
AT02767738T ATE428781T1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02767738T ATE428781T1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Country Status (13)

Country Link
US (5) US7199228B2 (de)
EP (2) EP1448986B1 (de)
JP (2) JP4504015B2 (de)
KR (2) KR100943567B1 (de)
AT (2) ATE325341T1 (de)
AU (2) AU2002330663B2 (de)
CA (2) CA2457789A1 (de)
DE (2) DE60211206T2 (de)
DK (1) DK1417307T3 (de)
ES (1) ES2325247T3 (de)
IL (4) IL160407A0 (de)
MX (2) MXPA04001480A (de)
WO (2) WO2003016567A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
AU2001251115A1 (en) * 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
JP4504015B2 (ja) * 2001-08-17 2010-07-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド アポトーシスを誘導するためのオリゴヌクレオチド組成物およびそれらの使用
WO2004014312A2 (en) * 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
CN102791291A (zh) * 2009-11-10 2012-11-21 拜昂尼科生命科学有限公司 含有非dna碱基的多核苷酸组合物和其用于调节免疫反应的用途
US8740314B2 (en) * 2011-01-11 2014-06-03 Joy Mm Delaware, Inc. Bit holding system with an opening for removal of broken bits
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
JP3124036B2 (ja) * 1995-01-19 2001-01-15 ジェン−プローブ・インコーポレーテッド ライム病関連ボレリアに対する核酸増幅オリゴヌクレオチドおよびプローブ
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
PT1171634E (pt) * 1999-04-08 2006-05-31 Gen Probe Inc Pares de iniciadores de amplificacao e de sequenciacao e sua utilizacao
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
JP4504015B2 (ja) * 2001-08-17 2010-07-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド アポトーシスを誘導するためのオリゴヌクレオチド組成物およびそれらの使用
EP1465910A4 (de) * 2002-02-20 2005-03-16 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung der genexpression von checkpointkinase-1 (chk-1) unter verwendung kurzer interferierender nukleinsäuren

Also Published As

Publication number Publication date
EP1417307A2 (de) 2004-05-12
US7200531B2 (en) 2007-04-03
MXPA04001315A (es) 2004-05-20
AU2002330663B2 (en) 2007-09-20
US20110160291A1 (en) 2011-06-30
ES2325247T3 (es) 2009-08-31
JP4469603B2 (ja) 2010-05-26
ATE428781T1 (de) 2009-05-15
KR101017483B1 (ko) 2011-02-25
US20080081793A1 (en) 2008-04-03
AU2002326067B2 (en) 2007-05-31
IL160408A (en) 2010-05-31
KR20040030138A (ko) 2004-04-08
CA2457789A1 (en) 2003-02-27
DE60211206T2 (de) 2006-10-26
JP2005509411A (ja) 2005-04-14
US7893242B2 (en) 2011-02-22
US20030144233A1 (en) 2003-07-31
DE60211206D1 (de) 2006-06-08
WO2003016528A2 (en) 2003-02-27
KR100943567B1 (ko) 2010-02-22
JP2005521119A (ja) 2005-07-14
US20030113763A1 (en) 2003-06-19
EP1417307B1 (de) 2009-04-15
US7199228B2 (en) 2007-04-03
CA2457783A1 (en) 2003-02-27
IL160408A0 (en) 2004-07-25
WO2003016567A2 (en) 2003-02-27
EP1448986B1 (de) 2006-05-03
WO2003016567A3 (en) 2004-06-03
EP1448986A2 (de) 2004-08-25
KR20040032925A (ko) 2004-04-17
MXPA04001480A (es) 2004-05-20
US8350016B2 (en) 2013-01-08
HK1069205A1 (en) 2005-05-13
IL160407A0 (en) 2004-07-25
JP4504015B2 (ja) 2010-07-14
DE60231986D1 (de) 2009-05-28
DK1417307T3 (da) 2009-07-13
IL160407A (en) 2010-02-17
WO2003016528A3 (en) 2003-10-09
US20080077372A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
DE69233599T2 (de) Unterbrochene 2'-modifizierte Oligonukleotide
ATE325341T1 (de) Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
BR9811805A (pt) Derivados quinazolina substituìda e seu uso como inibidores de quinase tirosina
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
DK0759927T3 (da) Pteridinnucleotidanaloger som fluorescerende DNA prober
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
ATE505474T1 (de) Inhibitoren von nukleosidphosphorylasen und nukleosidasen
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
DE602004022633D1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
BRPI0414019A (pt) nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos
TW200509892A (en) Novel aminobenzophenone compounds
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
TR200200278T2 (tr) Kalsilitik bileşimler
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE10393716D2 (de) Decoy-Oligonukleotid-Hemmung der CD40-Expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties